The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland

被引：0
|
作者：
Thomas Ward
Tray Brown
Ruth D. Lewis
Melodi Kosaner Kliess
Antonio Ramirez de Arellano
Carol M. Quinn
机构：
[1] Health Economics and Outcomes Research Ltd.,Health Economics Group, College of Medicine and Health
[2] University of Exeter,Vifor Pharma Group
[3] HEOR,undefined
[4] Vifor Pharma Group,undefined
[5] Medical Department,undefined
来源：
PharmacoEconomics - Open | 2022年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：757 / 771
页数：14
相关论文
共 50 条
  • [1] The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
    Ward, Thomas
    Brown, Tray
    Lewis, Ruth D.
    Kliess, Melodi Kosaner
    de Arellano, Antonio Ramirez
    Quinn, Carol M.
    PHARMACOECONOMICS-OPEN, 2022, 6 (05) : 757 - 771
  • [2] THE COST-EFFECTIVENESS OF PATIROMER FOR THE TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HEART FAILURE IN IRELAND
    Ward, T.
    Serna, Ramirez de Arellano A.
    Quinn, C.
    VALUE IN HEALTH, 2022, 25 (01) : S95 - S95
  • [3] THE COST-EFFECTIVENESS OF PATIROMER FOR THE TREATMENT OF HYPERKALAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HEART FAILURE IN THE UK
    Ward, T.
    Baxter, G.
    Serna, Ramirez de Arellano A.
    VALUE IN HEALTH, 2022, 25 (01) : S43 - S43
  • [4] A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
    Thomas Ward
    Ruth D. Lewis
    Tray Brown
    Garth Baxter
    Antonio Ramirez de Arellano
    BMC Nephrology, 24
  • [5] A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
    Ward, Thomas
    Lewis, Ruth D.
    Brown, Tray
    Baxter, Garth
    de Arellano, Antonio Ramirez
    BMC NEPHROLOGY, 2023, 24 (01)
  • [6] A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain
    Ramon Gonzalez-Juanatey, Jose
    Gonzalez-Franco, Alvaro
    de Sequera, Patricia
    Valls, Marta
    Ramirez de Arellano, Antonio
    Pomares, Elisenda
    Nieves, Diana
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 640 - 649
  • [7] Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
    Pitt, Bertram
    Bushinsky, David A.
    Kitzman, Dalane W.
    Ruschitzka, Frank
    Metra, Marco
    Filippatos, Gerasimos
    Rossignol, Patrick
    Du Mond, Charles
    Garza, Dahlia
    Berman, Lance
    Lainscak, Mitja
    ESC HEART FAILURE, 2018, 5 (03): : 257 - 266
  • [8] Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
    Pitt, Bertram
    Bakris, George L.
    Bushinsky, David A.
    Garza, Dahlia
    Mayo, Martha R.
    Stasiv, Yuri
    Christ-Schmidt, Heidi
    Berman, Lance
    Weir, Matthew R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (10) : 1057 - 1065
  • [9] Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
    Slawik, Jonathan
    Dederer, Juliane
    Kindermann, Ingrid
    Boehm, Michael
    ESC HEART FAILURE, 2020, 7 (05): : 3161 - 3164
  • [10] Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
    Weir, Matthew R.
    Mayo, Martha R.
    Garza, Dahlia
    Arthur, Susan A.
    Berman, Lance
    Bushinsky, David
    Wilson, Daniel J.
    Epstein, Murray
    JOURNAL OF HYPERTENSION, 2017, 35 : S57 - S63
12345